Radical Prostatectomy Without Prior Biopsy? Final Histopathology of Radical Prostatectomies in 103 Consecutive Biopsy-naïve Patients Who Underwent Radical Prostatectomy [0.03%]
未经活检的前列腺根治术？103例未行穿刺活检即接受前列腺根治术患者的最终病理结果分析
Marie Semmler,Julian Marcon,Elena K Berg et al.
Marie Semmler et al.
Background and objective: Prostate biopsy for histological confirmation is the standard before radical prostatectomy (RP). However, some patients refuse biopsy despite highly suspicious imaging findings. This study aimed ...
En-bloc Resection of Bladder Tumor Versus Conventional Transurethral Resection of Bladder Tumor: Long-term Oncological Outcomes from a Single-center Prospective Trial [0.03%]
膀胱肿瘤整块切除与传统经尿道膀胱肿瘤电切的长期疗效：单中心前瞻性试验结果
Francesco Di Bello,Pietro Diana,Andrea Gallioli et al.
Francesco Di Bello et al.
Prior randomized trials have shown that en bloc transurethral resection of bladder tumor (ERBT) is noninferior to conventional transurethral resection of bladder tumor (cTURBT) for pathological staging. To address gaps in long-term oncologi...
Performance of Urine Tumor DNA Detection in Patients with High-grade Non-muscle-invasive Bladder Cancer Undergoing Repeat Transurethral Resection [0.03%]
高危非肌层浸润性膀胱癌患者经尿道膀胱肿瘤切除术后复查中尿液肿瘤DNA检测的应用价值
Jay Ogunkeye,Eugene Shkolyar,Kathleen E Mach et al.
Jay Ogunkeye et al.
Background and objective: Patients with high-risk non-muscle invasive bladder cancer (NMIBC) experience high recurrence rates and potential understaging, supporting guideline recommendations for repeat transurethral resec...
Repeated Renal Interventions for Renal Cell Carcinoma in von Hippel-Lindau Disease: Long-Term Outcomes [0.03%]
Von Hippel-Lindau病反复肾脏介入治疗肾细胞癌的长期疗效分析
C A Jilg,S C Astheimer,F Kotsis et al.
C A Jilg et al.
Von Hippel-Lindau (VHL) disease is a hereditary cancer syndrome frequently associated with recurrent renal cell carcinoma (RCC), often requiring multiple renal interventions. Data on the timing and outcomes of repeated renal procedures rema...
Ureteroscopy in Patients Receiving Systemic Anticoagulants: A Systematic Review and Meta-analysis of Safety, Efficacy, and Perioperative Management [0.03%]
全身抗凝患者尿路镜检查的系统评价和元分析：安全性、有效性和围手术期管理
Donnacha Hogan,Stefanie M Croghan,Bhaskar K Somani et al.
Donnacha Hogan et al.
Context: To evaluate the safety and efficacy of ureteroscopy (URS) in adults receiving systemic anticoagulant (AC) therapy, including vitamin K antagonists and direct oral anticoagulants (DOACs), compared with non-AC cont...
Discordant Response in Pelvic Lymph Nodes and Cystectomy Specimens After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer [0.03%]
新辅助化疗后肌层浸润性膀胱癌盆腔淋巴结与全膀胱切除标本的不一致反应
Luca Antonelli,Luca Afferi,Francesco Del Giudice et al.
Luca Antonelli et al.
Background: Radical cystectomy with pelvic lymph node dissection (PLND) remains the standard treatment for muscle-invasive bladder cancer (MIBC). Neoadjuvant chemotherapy (NAC) improves survival, and recent immunochemothe...
PSMA Therapy Grey Zones: Actinium, Lutetium, or Terbium for the Future of Radioligand therapy? [0.03%]
PSMA治疗的灰色地带：锕、镥还是铽将成为放射配体治疗的未来？
Valentino Dragonetti,Francesco Mattana,Francesco Ceci
Valentino Dragonetti
Background: Radioligand therapy targeting the prostate-specific membrane antigen (PSMA) has been established as a key treatment for PSMA-positive metastatic castration-resistant prostate cancer following the approval of [...
Seeking a Credible Basis for Prostatic Obstruction as the Reversible Cause of Other Lower Urinary Tract Dysfunctions [0.03%]
探寻前列腺梗阻作为其他下尿路功能障碍可逆原因的可信依据
Marcus J Drake,Kari A O Tikkinen
Marcus J Drake
Lower urinary tract symptoms (LUTS) and various lower urinary tract dysfunctions (LUTDs) often coexist because their prevalence increases with ageing. In men, benign prostatic obstruction (BPO) is often proposed as a cause of other "seconda...
Dose-intensified PSMA Radioligand Therapy: The Rationale Behind the OPTIMAL-PSMA Trial [0.03%]
剂量强化的PSMA放射配体治疗：OPTIMAL-PSMA试验的背后理由
Gemma Sheehan-Dare,Sobia Khan,Louise Emmett
Gemma Sheehan-Dare
A key unanswered question in prostate-specific membrane-antigen (PSMA) targeted radioligand therapy is whether we have chosen therapy doses and regimens that are "safe" rather than "effective," with phase 3 trials to date guided by conserva...
Reply to Schwartzmann and Silvestri's Letter to the Editor re: Ritter Manuel, Stein Johannes, Barber Neil, et al. WATER III: A Prospective, Partially Randomized Trial of Aquablation Therapy Versus Transurethral Laser Enucleation of the Prostate for Treatment of Lower Urinary Tract Symptoms. Eur Urol Focus 2026;12:266-274 [0.03%]
对Schwartzmann和Silvestri关于Ritter等人文章的来信回复：WATER III：一项前瞻性部分随机试验，比较水动力剜除术与经尿道激光前列腺剜除术治疗下尿路症状的效果。Eur Urol Focus 2026;12:266-274
Manuel Ritter,Robert Németh,Matthias Schmid et al.
Manuel Ritter et al.